Priority research needs include large-scale randomized controlled trials to establish efficacy and safety, dose-ranging studies to optimize treatment protocols, long-term safety studies particularly regarding cancer risk, and comparative effectiveness research with established therapies
BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels in a dose- and time-dependent manner
Onze aandacht en betrokkenheid leidt tot optimale oplossingen
International Journal of Pharmaceutics 1999
BPC-157 5mg is typically reconstituted with 2 ml of bacteriostatic water, yielding a 2.5 mg/ml (2,500 mcg/ml) working solution
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America